InspireMD Inc. (NSPR)

NASDAQ: NSPR · IEX Real-Time Price · USD
1.93
0.00 (0.00%)
At close: Aug 12, 2022 3:58 PM
1.91
-0.02 (-1.04%)
After-hours: Aug 12, 2022 6:38 PM EDT
0.00%
Market Cap 16.06M
Revenue (ttm) 5.17M
Net Income (ttm) -17.29M
Shares Out 8.32M
EPS (ttm) -2.08
PE Ratio n/a
Forward PE 11.70
Dividend n/a
Ex-Dividend Date n/a
Volume 13,039
Open 1.90
Previous Close 1.93
Day's Range 1.90 - 1.99
52-Week Range 1.68 - 5.06
Beta 1.29
Analysts Buy
Price Target 5.36 (+177.7%)
Earnings Date Aug 9, 2022

About NSPR

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as byp... [Read more...]

Industry Health Care Equipment & Supplies
CEO Marvin Slosman
Employees 50
Stock Exchange NASDAQ
Ticker Symbol NSPR
Full Company Profile

Financial Performance

In 2021, InspireMD's revenue was $4.50 million, an increase of 80.89% compared to the previous year's $2.49 million. Losses were -$14.92 million, 41.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for NSPR stock is "Buy." The 12-month stock price forecast is 5.36, which is an increase of 177.72% from the latest price.

Price Target
$5.36
(177.72% upside)
Analyst Consensus: Buy
Stock Forecasts

News

InspireMD Reports Second Quarter 2022 Financial Results and Provides Business Update

- Generated 47.8% growth in CGuard™ revenue year-over-year -

InspireMD to Report Second Quarter 2022 Financial Results on August 9, 2022, and Provide Corporate Business Update

- Conference call and webcast to be held at 8:30 a.m. EDT -

InspireMD Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor

Credited with performing the first ever endovascular repair procedure in 1990 Credited with performing the first ever endovascular repair procedure in 1990

InspireMD Provides Highlights from Recent Presentations and Live Case Transmission at LINC 2022

Successful live case transmission again demonstrated CGuard's™ differentiated patient protection features and ease of use Successful live case transmission again demonstrated CGuard's™ differentiated pa...

5 Stocks To Watch For June 6, 2022

Some of the stocks that may grab investor focus today are: Wall Street expects Science Applications International Corporation (NYSE: SAIC) to report quarterly earnings at $1.77 per share on revenue of $...

Other symbols: COUPHQYOPSAIC

InspireMD's CGuard™ Embolic Prevention Stent System to be Featured in Clinical Presentations and a Live Case Transmis...

Live case transmission designed to demonstrate ease-of-use and exceptional patient safety features of CGuard™ Embolic Prevention System (EPS) Live case transmission designed to demonstrate ease-of-use a...

InspireMD Reports First Quarter 2022 Financial Results and Business Update

- 20% growth in CGuard™ revenue Year-over-Year -

InspireMD to Report First Quarter 2022 Financial Results on May 10, 2022 and Provide Corporate Business Update

Earnings Conference Call to be held Tuesday, May 10, 2022, at 8:30 a.m. ET Earnings Conference Call to be held Tuesday, May 10, 2022, at 8:30 a.m. ET

InspireMD to Host Key Opinion Leader Event on Carotid Artery Disease Management and Stroke Prevention in combination ...

Tuesday, March 22nd @ 2 p.m. ET Tuesday, March 22nd @ 2 p.m. ET

InspireMD Reports Fourth Quarter and Year-End 2021 Financial Results

- CGuard™ Revenue Generated 87.5% growth over Q4'20 and 55.9% Year-over-Year –-

InspireMD to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022 and Provide Corporate Busine...

-Earnings Conference Call to be held Tuesday, March 8, 2022, at 8:30 a.m. ET-

InspireMD to Present at the 16th Biennial Scientific Meeting of the International Andreas Gruentzig Society (IAGS)

- Biennial Scientific Meeting of the IAGS to be held from January 31st – February 3rd 2022 - - Biennial Scientific Meeting of the IAGS to be held from January 31st – February 3rd 2022 -

Seeking Income in Challenging Times for Retirement Portfolios

It's been a shaky start to the year for markets as a hawkish Fed, and the prospect of rising rates has many advisors looking further afield for income opportunities. Strategies that have carried retirem...

InspireMD Announces Live Case Broadcast at ISET 2022 Conference Following the Supplement Approval by the FDA Regardin...

Live Case will be Broadcasted Today at 11:00am ET Live Case will be Broadcasted Today at 11:00am ET

InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update

-CGuard™ sales generated 24% YoY revenue growth-

InspireMD to Report Third Quarter 2021 Financial Results on November 9, 2021 and Provide Corporate Business Update

Earnings Conference Call to be held Tuesday, November 9, 2021, at 8:30 a.m. ET Earnings Conference Call to be held Tuesday, November 9, 2021, at 8:30 a.m. ET

InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority fo...

TEL AVIV, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Dis...

2 Net Current Asset Value Stock Picks to Consider

There are some investors who purchase U.S.-listed stocks that are trading below their liquidation values because they believe they can get a huge return out of these stocks after the market has reapprai...

Other symbols: QD

InspireMD Announces Strong Second Quarter 2021 Financial Results

Revenue rebound, strong procedural recovery

InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of...

TEL AVIV, Israel, July 23, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD...

InspireMD to Present at the LD Micro Virtual Invitational Conference on June 9, 2021

TEL AVIV, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq-CM: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disea...

InspireMD Commences Trading on Nasdaq-CM

Ticker to remain NSPR Ticker to remain NSPR

InspireMD to Participate at the Investor Summit Conference and Present to Investors on May 17, 2021

TEL AVIV, Israel, May 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of ...

InspireMD Announces Appointment of Katie Arnold to Board of Directors

TEL AVIV, Israel, May 12, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of...

InspireMD Announces First Quarter 2021 Financial Results

Company Completes Up-List to Nasdaq Capital Market, with Trading Becoming Effective May 21, 2021